Novel & Dual Payloads: Assessing Linker Conjugation Technologies That Encourage Flexibility in Payloads

Time: 4:00 pm
day: Day One P3

Details:

  • Evaluating the right ratios, the advantages of releasing drugs in specific ratios, and which combination of drugs make sense when considering dual payloads
  • Discussing how novel payloads hold promise to overcome drug resistance
  • Advancing cytoxic or immune-stimulating payloads with novel MoAs

Speakers:

Hans-Peter Gerber Hans-Peter brings 30 years of R&D experience in oncology drug development, specializing in antibody-drug conjugates (ADCs), redirected T-cell targeting compounds (bispecifics), and adoptive T-cell therapies Read more
Bob Lutz Bob is the CSOof Iksuda Therapeutics, after being Vice President of Tanslational R&D at ImmunoGen. Whilst at ImmunoGen, Bob was directly responsible for the development Read more
Patrick Beusker Patrick is an experienced professional in the field of medicinal and protein chemistry, currently serving as the Director of Medicinal & Protein Chemistry at Byondis Read more
Zou Bin
Robin Carr Robin joined Myricx in Nov 2019 as chief development officer and became CEO in August 2022. Prior to Myricx, Robin was at GSK where he Read more